Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

BACKGROUND: Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Humby, Frances, Durez, Patrick, Buch, Maya H, Lewis, Myles J, Rizvi, Hasan, Rivellese, Felice, Nerviani, Alessandra, Giorli, Giovanni, Mahto, Arti, Montecucco, Carlomaurizio, Lauwerys, Bernard, Ng, Nora, Ho, Pauline, Bombardieri, Michele, Romão, Vasco C, Verschueren, Patrick, Kelly, Stephen, Sainaghi, Pier Paolo, Gendi, Nagui, Dasgupta, Bhaskar, Cauli, Alberto, Reynolds, Piero, Cañete, Juan D, Moots, Robert, Taylor, Peter C, Edwards, Christopher J, Isaacs, John, Sasieni, Peter, Choy, Ernest, Pitzalis, Costantino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829614/
https://www.ncbi.nlm.nih.gov/pubmed/33485455
http://dx.doi.org/10.1016/S0140-6736(20)32341-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829614/
https://www.ncbi.nlm.nih.gov/pubmed/33485455
http://dx.doi.org/10.1016/S0140-6736(20)32341-2

Ejemplares similares